Hiroaki Nagano

Hiroaki Nagano

Auto-generated profile, based on publicly available information

Hiroaki Nagano

Research Division, Chugai Pharmabody Research, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
YIYuka Inoue
Yuka Inoue
Shoichi HazamaShoichi Hazama
Shoichi Hazama
NSNobuaki Suzuki
Nobuaki Suzuki
YTYukio Tokumitsu
Yukio Tokumitsu
SKShinsuke Kanekiyo
Shinsuke Kanekiyo
HNHiroaki Nagano
Hiroaki Nagano
Cetuximab has activity against colorectal cancers. Recent studies demonstrated that cetuximab induces antibody‐dependent cell‐mediated cytotoxicity via immune cells, and a new immune‐related mechanism of inducing immunogenic cell death. This study aimed to evaluate the immune responses induced by cetuximab in tumor microenvironments at liver metastasis sites of metastatic colorectal cancer patients. We assessed immune cell infiltration in the liver metastatic sites of 53 colorectal cancer patients. These patients were divided into three groups according to the treatment before operation: chemotherapy with cetuximab, chemotherapy without cetuximab, and no chemotherapy. The inflammatory cells in the liver metastatic sites were assessed by hematoxylin–eosin staining, focusing on the invasive margin. The overall inflammatory reaction and number of lymphoid cells were assessed with a four‐point scoring system. We then assessed immune cell infiltration (CD3, CD8 and CD56) in 15 liver metastatic sites. Hematoxylin–eosin staining demonstrated more inflammatory cells in the chemotherapy with cetuximab group than in the other groups (P < 0.001). Of note, inflammatory cells were found in intratumoral areas, and the destruction of cancer cell foci was observed in the chemotherapy with cetuximab group. Moreover, a higher infiltration of CD3+ (P = 0.003), CD8+ (P = 0.003) and CD56+ (P = 0.001) cells was observed in the chemotherapy with cetuximab group than in the other groups. These results suggest that cetuximab might have an immune‐enhancing effect. As such, the immune‐related mechanism of action of cetuximab may enhance the efficacy of combination therapy, such as chemotherapy and immunotherapy using therapeutic peptides.

2 April 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
HMHirofumi Mikami
Hirofumi Mikami
SFShu Feng
Shu Feng
YMYutaka Matsuda
Yutaka Matsuda
SIShinya Ishii
Shinya Ishii
SNSotaro Naoi
Sotaro Naoi
TITomoyuki Igawa
Tomoyuki Igawa
Small-cell lung cancer (SCLC) is an aggressive cancer for which immune checkpoint inhibitors (ICI) have had only limited success. Bispecific T-cell engagers are promising therapeutic alternatives for ICI-resistant tumors, but not all patients with SCLC are responsive. Herein, to integrate CD137 costimulatory function into a T-cell engager format and thereby augment therapeutic efficacy, we generated a CD3/CD137 dual-specific Fab and engineered a DLL3-targeted trispecific antibody (DLL3 trispecific). The CD3/CD137 dual-specific Fab was generated to competitively bind to CD3 and CD137 to prevent DLL3-independent cross-linking of CD3 and CD137, which could lead to systemic T-cell activation. We demonstrated that DLL3 trispecific induced better tumor growth control and a marked increase in the number of intratumoral T cells compared with a conventional DLL3-targeted bispecific T-cell engager. These findings suggest that DLL3 trispecific can exert potent efficacy by inducing concurrent CD137 costimulation and provide a promising therapeutic option for SCLC.

1 May 2011 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
YTYoshito Tomimaru
Yoshito Tomimaru
HEHidetoshi Eguchi
Hidetoshi Eguchi
HWHiroshi Wada
Hiroshi Wada
ATAkira Tomokuni
Akira Tomokuni
SKShogo Kobayashi
Shogo Kobayashi
HNHiroaki Nagano
Hiroaki Nagano
Interferon (IFN)-ß is reported to have more potent antitumor effects than IFN-α. The aim of this study was to compare the synergistic antitumor activity of both IFNs when combined with gemcitabine on cultured pancreatic cancer cells expressing various levels of IFN receptor. The growth-inhibitory effects of IFN-α and IFN-ß in combination with gemcitabine on three human pancreatic cancer cell lines (BxPC-3, MIAPaCa-2, Panc-1) were evaluated by MTT assay and isobolographic analysis. We also correlated their growth-inhibitory effects with the expression status of type I IFN receptor type 2 (IFNAR2). Western blot analysis indicated strong expression of IFNAR2 in BxPC-3 and MIAPaCa-2, but weak expression in Panc-1. The growth-inhibitory effect of gemcitabine was enhanced synergistically by IFN-α in BxPC-3 and MIAPaCa-2, but not in Panc-1. IFN-ß exhibited more potent synergistic growth-inhibitory effects with gemcitabine in BxPC-3 and MIAPaCa-2 compared to IFN-α, and also synergistic enhancement in Panc-1. In conclusion, our results indicated that the growth-inhibitory effect of IFN-ß with gemcitabine was synergistic not only in pancreatic cancer cells with strong expression of IFNAR2, but also in those with weak expression of IFNAR2.

4 June 2024
Verified
Other
Open access
PDF file
HMHirofumi Mikami
Hirofumi Mikami
SFShu Feng
Shu Feng
YMYutaka Matsuda
Yutaka Matsuda
SIShinya Ishii
Shinya Ishii
SNSotaro Naoi
Sotaro Naoi
TITomoyuki Igawa
Tomoyuki Igawa
Pharmacokinetic parameters of DLL3 trispecific in cynomolgus monkeys

17 June 2026
Verified
Other
Open access
HMHirofumi Mikami
Hirofumi Mikami
SFShu Feng
Shu Feng
YMYutaka Matsuda
Yutaka Matsuda
SIShinya Ishii
Shinya Ishii
SNSotaro Naoi
Sotaro Naoi
TITomoyuki Igawa
Tomoyuki Igawa
Supplementary Figure S3. Binding of DLL3 trispecific to FcγRs, C1q, and FcRn. (

17 June 2026
Verified
Other
Open access
HMHirofumi Mikami
Hirofumi Mikami
SFShu Feng
Shu Feng
YMYutaka Matsuda
Yutaka Matsuda
SIShinya Ishii
Shinya Ishii
SNSotaro Naoi
Sotaro Naoi
TITomoyuki Igawa
Tomoyuki Igawa
Supplementary Figure S1. The composition of the antibodies